The red-hot life sciences market in and around Boston is lacking a critical piece as its growing companies look to expand.
Biomanufacturing facilities are few and far between in the region, and biopharmaceutical companies are scrambling for solutions, experts said. New medicines require fundamentally different manufacturing than the drugs of the past, meaning most of these facilities need to be built new.
“There’s a dire shortage of this kind of real estate,” King Street Properties principal Stephen Lynch said. “There doesn’t exist, in the U.S., an organized real estate market for this product type. The end users, the companies that need to make these drugs, are scrambling for…
Read the full story here.
|